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Background: Heart rate and systolic blood pressure (SBP) are prognostic markers in heart failure
(HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as
well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear.
Hypothesis: RPP and its components are associated with HFpEF outcomes.
Methods: We performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in
Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov
NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventric-
ular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as
well as the change of these variables using adjusted Cox models.
Results: After multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and
RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per
5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all
P < 0.05). Baseline SBP was associated with 180-day mortality (HR: 0.88 per 10-mm Hg,
P = 0.028). Though change in RPP was associated with 30-day mortality/HF hospitalization, the
RPP baseline variable did not provide additional associative information with regard to out-
comes when compared with assessment of baseline heart rate and SBP variables alone.
Conclusions: An increase in heart rate and SBP from baseline to discharge was associated with
increased 30-day mortality/HF hospitalization in HFpEF patients with acute exacerbation.
These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.
KEYWORDS
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1 | INTRODUCTION
Heart failure (HF) affects >5.5 million people in the United States,
with 870 000 individuals diagnosed each year.1 Although patients
with heart failure with preserved ejection fraction (HFpEF) have simi-
lar symptoms as patients who have heart failure with reduced ejection
fraction (HFrEF), there are clear distinctions from patients with HFrEF,
as evidenced by an association with older age and increased comor-
bidity burden and a lack of medical therapies that improve clinical out-
comes in HFpEF.2–4
Several studies have established that baseline heart rate is ele-
vated in patients with HF. Many of these studies, however, investi-
gated HFrEF or did not distinguish HFpEF from HFrEF. In an analysis
of patients with HFrEF hospitalized for HF, heart rate > 70 bpm was
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DOI: 10.1002/clc.22981
Clinical Cardiology. 2018;41:945–952. wileyonlinelibrary.com/journal/clc © 2018 Wiley Periodicals, Inc. 945
predictive of post-discharge mortality.5 Studies have also shown
improvement in mortality, morbidity, exercise tolerance, quality of life,
and left ventricular ejection fraction (LVEF) in ambulatory patients
with HF when heart rate was reduced with β-blockade.6–11 Further-
more, underlying elevation in systolic blood pressure (SBP) is common
in patients with HFpEF. Acute hypertensive episodes may also cause
HF exacerbations and are typically a modifiable and treatable condi-
tion in these individuals.12
Both heart rate and blood pressure are incorporated in the rate
pressure product (RPP), an indirect index of myocardial oxygen con-
sumption that predicts cardiac function, morbidity, and mortality in
patients with cardiovascular disease. Myocardial oxygen consumption
can be assessed in HF patients via invasive hemodynamic monitoring
with right-heart catheterization and/or pulmonary artery catheteriza-
tion.13–15 However, the simple measure of RPP may provide useful
information in a noninvasive manner to risk-stratify and offer prog-
nostic information for patients.16
The goal of this study was to examine heart rate, SBP, and RPP in
hospitalized patients with HFpEF enrolled in the Acute Study of Clini-
cal Effectiveness of Nesiritide in Subjects With Decompensated Heart
Failure (ASCEND-HF) trial to better understand how these factors at
baseline and their change over time may be associated with clinical
outcomes.
2 | METHODS
Acute Study of Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT0047
6852) was a randomized controlled trial that investigated nesiritide vs
placebo in patients hospitalized for acute decompensated HF regard-
less of LVEF. The design, rationale, and primary results have been
published.17,18 The study enrolled 7141 patients between May 2007
and August 2010 at 398 centers across the world, with institutional
review board or ethics approval obtained at each study site and all
patients providing informed consent for participation.
LVEF was obtained from case-report forms for participants; the
timing and method by which LVEF was ascertained were site-specific
and not based on trial protocol. Patients without LVEF measurement
were excluded from this analysis. Given the American College of Car-
diology/American Heart Association (ACC/AHA) definition of HFrEF
as LVEF <40%, variable definitions of HFrEF and HFpEF in the litera-
ture, and prior study of LVEF in ASCEND-HF that suggested similar
baseline features of LVEF 40% to 50% to those with LVEF >50%,
HFpEF included all patients with LVEF ≥40% and HFrEF included
those with LVEF <40%.19
Vital signs, including heart rate and blood pressure, were mea-
sured at multiple time points per trial protocol. Baseline heart rate and
SBP were defined as measurements taken at the time of randomiza-
tion. Discharge heart rate and SBP were defined as measurements
taken at the time of discharge or day 10, whichever came first.
Change in heart rate and SBP was the absolute difference between
measurement at discharge and baseline. RPP was calculated by multi-
plying heart rate and SBP.
2.1 | Statistical analysis
Baseline patient characteristics were reported for HFpEF patients
based on heart rate and SBP dichotomized at the median split for each
variable and compared using Pearson χ2 tests or Fisher exact tests for
categorical variables and Wilcoxon rank-sum tests for continuous vari-
ables. The survival distributions between groups were compared using
Kaplan–Meier event curves with log-rank test.
The primary outcome of interest was the composite endpoint of
30 day all-cause mortality and rehospitalization for HF; the secondary
outcome of interest was all-cause mortality at 180 days. Endpoints
were redefined to start from the time of hospital discharge or at
10 days from randomization, whichever came first. Thus patients who
died from the time of randomization to discharge or at 10 days were
not included in this analysis. The relationship between baseline heart
rate (as a continuous variable) and outcomes was evaluated using Cox
proportional hazards regression in HFpEF patients. Models were
adjusted based on variables consistently used in ASCEND-HF post-
hoc analyses that included age, blood urea nitrogen, baseline sodium,
and baseline dyspnea.20,21 Additional adjustment was made with
regard to variables that were thought to potentially confound out-
come associations in the present analysis: randomization to nesiritide,
use of β-blocker, use of calcium channel blocker, implantable
cardioverter-defibrillator, and presence of pacemaker. Among patients
discharged alive, we evaluated the association between in-hospital
change in heart rate and outcomes using Cox models, adjusted for
baseline heart rate and an indicator for length of stay >10 days. This
analysis was repeated for HFrEF patients. Further, to assess whether
the associations between heart rate and outcomes were similar for
HFpEF and HFrEF patients, we modeled the interaction of heart rate
and HFpEF/HFrEF status in Cox models. Analyses were repeated in a
similar way for SBP and RPP.
Proportional hazards and linearity assumptions were assessed for
the primary exposure variables and adjustment covariates. No viola-
tions were identified for heart rate, SBP, or RPP, and transformations
for adjustment covariates were made when appropriate. Multiple
imputation with 25 imputations was used for missing data; final
results reflect the combined result across all imputations accounting
for variation due to missing data. A P value <0.05 was considered sig-
nificant. Given the exploratory nature of this analysis, there was no
adjustment for multiple comparisons. All statistical analyses were per-
formed using SAS software, version 9.3 (SAS Institute, Inc., Cary, NC).
3 | RESULTS
Of the 7007 patients enrolled in the ASCEND-HF trial with measured
LVEF, 737 (10.5%) had HFpEF. Patient characteristics according to
heart rate and SBP are presented in Table 1. Patients with lower heart
rate had more comorbidities, including hypertension (HTN), diabetes,
COPD, and coronary artery disease, and were more likely to be taking
β-blockers or calcium channel blockers at baseline in addition to hav-
ing a pacemaker compared with patients with higher heart rates.
Patients with lower SBP were on similar medical therapy compared
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with those with higher SBP, with the exception of aldosterone antag-
onists, which were more common in the lower-SBP group.
Table 2 presents unadjusted and adjusted clinical outcomes in
HFpEF. There were 79 deaths or HF rehospitalizations at 30 days and
85 deaths at 180 days. Baseline heart rate and RPP were not associ-
ated with primary or secondary outcomes after multivariable adjust-
ment. Baseline SBP was associated with 180-day all-cause mortality
in both unadjusted and adjusted Cox models and is further
demonstrated in the Figure 1. Changes in heart rate, SBP, and RPP
from baseline to discharge were each associated with significant
increases in 30-day mortality and HF rehospitalization in both unad-
justed and adjusted models, but none of the variables looking at in-
hospital change were associated with 180-day all-cause mortality.
Similar analyses were performed in patients with HFrEF (Table 3).
There were 247 deaths or HF rehospitalizations at 30 days and
316 deaths at 180 days. In these patients, higher baseline heart rate
TABLE 1 Baseline characteristics by heart rate and SBP in patients with HFpEF
Patient Characteristics
Heart Rate, bpm SBP, mm Hg
≤75, N = 370 >75, N = 367 ≤130, N = 393 >130, N = 344
Mean age, y 75 (67–82)a 72 (61–80)a 75 (67–81)a 72 (62–81)a
Female sex 49.2 48.2 49.6 47.7
Race
White 73.2 67.8 72.0 68.9
Black 15.1 18.3 14.5 19.2
Asian 8.6 12.3 11.2 9.6
Other 3.0 1.6 2.3 2.3
BMI, kg/m2 29 (26–34) 29 (25–34) 29 (25–32)a 30 (26–35)a
Medical history
HTN 89.5a 82.8a 81.4a 91.6a
DM 53.5a 46.3a 45.8a 54.7a
AF/flutter 48.6 52.0 54.7a 45.3a
COPD 29.7a 20.7a 28.5a 21.5a
CAD 67.3a 57.8a 63.6 61.3
Laboratory values
Na, mmol/L 140 (137–142) 139 (137–141) 139 (136–141)a 140 (137–142)a
Cr, mg/dL 1.3 (1.0–1.7) 1.2 (1.0–1.5) 1.3 (1.0–1.6) 1.2 (1.0–1.7)
Hb, g/dL 11.9 (10.6–13.4) 12.2 (11.0–13.7) 12.2 (10.9–13.6) 12.0 (10.8–13.3)
NT-proBNP, pg/mL 3184 (1633–7154) 4339 (2078–7833) 3727 (2128–8117) 3675 (1612–6381)
Medications and devices
β-Blocker 73.8a 61.9a 65.1 70.9
ACEI/ARB 60.8 62.1 59.8 63.4
Aldosterone antagonist 16.5 16.3 19.1a 13.4a
CCB 30.3a 21.0a 24.4 27.0
Digoxin 11.6 14.4 14.0 11.9
Nitrate 29.2a 18.8a 22.1 26.2
ICD 6.2 6.3 6.4 6.1
Biventricular pacemaker 5.1 3.0 3.8 4.4
Pacemaker 20.0a 8.4a 17.8a 10.2a
HF history
LVEF, % 50 (45–60) 50 (43–55) 50 (45–60) 50 (44–60)
NYHA class
I 3.7 9.4 7.2 5.8
II 31.6 22.7 28.7 25.3
III 41.9 26.4 43.3 45.1
IV 22.8 21.6 20.8 23.7
Ischemic etiology 68.9a 60.2a 65.6 63.4
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD, cor-
onary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; Cr, creatinine; DM, diabetes mellitus; Hb, hemoglobin;
HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; ICD, implantable cardioverter-defibrillator; IQR, interquartile
range; LVEF, left ventricular ejection fraction; Na, sodium; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SBP,
systolic blood pressure. Data are presented as % of N or median (IQR).
a Indicates P < 0.05 for comparison.
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was associated with increased 180-day all-cause mortality in adjusted
models. Further, higher baseline SBP was associated with significantly
reduced 30-day death or HF rehospitalization and 180-day all-cause
mortality. Increase in heart rate from baseline to discharge was also
associated with increased 30-day death or HF rehospitalization and
180-day all-cause mortality. Change in SBP from baseline to discharge
was not associated with the primary outcome but was associated with
180-day all-cause mortality. Change in RPP from baseline to discharge
was associated with a modest increase in 30-day mortality and HF
rehospitalization.
Interaction analyses comparing HFpEF and HFrEF populations
were not significant for baseline heart rate, SBP, RPP, or the change
in any variable with regard to both the primary and secondary out-
comes (all P > 0.05).
4 | DISCUSSION
In the present analysis, we assessed the association of baseline heart
rate, SBP, and RPP in HFpEF patients with acute exacerbation as well
as associations between in-hospital changes in these values and post-
discharge outcomes. We found that in-hospital changes in each of
these parameters were associated with short-term clinical outcomes
(30-day mortality or HF hospitalization) in HFpEF, but that only base-
line SBP was associated with 180-day mortality in HFpEF. There was
also insufficient evidence to support an interaction between these
variables and outcome associations based on LVEF.
We found that an increase in SBP and/or heart rate from baseline
to discharge in patients with HFpEF was associated with worse
outcomes—this in contrast to our findings of higher baseline SBP
being associated with lower 180-day all-cause mortality and no asso-
ciation of baseline heart rate with outcomes. An elevated baseline
SBP could precipitate an acute HF exacerbation and effectively be
treated with medications, leading to improved outcomes. However,
when SBP increases during hospitalization, this may be an indicator of
uncontrolled HTN or HTN refractory to standard medical therapy.
Indeed, antihypertensive therapy is a key component to managing
HF and also to preventing HFpEF.19 Long-standing HTN increases left
ventricular (LV) mass, causing an inability to appropriately fill the LV
and maintain cardiac output. Antihypertensive agents have been
shown to reduce LV mass and the development of HFpEF.22–24 The
landmark Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) study included 404 patients with HFpEF
and showed reduced rates of HFpEF in patients on chlorthalidone and
a reduced risk for HF hospitalization.25 Although there are several
studies demonstrating improvement in symptoms with blood-pressure
reduction in acute HF patients with HTN, the impact of blood-
pressure control in the acute setting on clinical outcomes and in the
HFpEF population in particular has not been well studied.26,27
In the Treatment of Preserved Cardiac Function Heart Failure
With an Aldosterone Antagonist (TOPCAT) study, re-analysis of the
data in the Americas alone showed no significant relationship
between SBP and outcomes, suggesting the beneficial effects of spir-
onolactone were independent of blood-pressure effects.28 However,
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control and thus further reduction of already-controlled blood pres-
sure may not show additional benefit in patients with HFpEF.
A few recent studies have also examined the impact of low SBP
in HF. In a retrospective analysis of ASCEND-HF, patients who expe-
rienced an episode of hypotension during acute decompensated HF
admission had an associated higher 30-day mortality compared with
those without a hypotensive episode.29 Although this analysis did not
specifically look at HFpEF patients, it included this cohort, which
appears to have similar event rates of hypotension during hospitaliza-
tion to those with HFrEF, suggesting that in addition to increase in
blood pressure during hospitalization, perhaps a decrease in blood
pressure—if only transiently—to a hypotensive state may also be detri-
mental. In an observational study of the Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients With Heart Failure
(OPTIMIZE-HF), a registry of patients hospitalized with HF that has
been linked with Medicare, the association of the change SBP by
20 mm Hg from admission to discharge as well as discharge SBP was
assessed.30 Change (increase or decrease) in SBP and discharge SBP
<120 mm Hg were associated with increased all-cause mortality.30
Our data support that an increase in SBP is associated with worse
outcomes; however, there are key differences in the studies, including
HFpEF definitions and outcomes assessed, in addition to the assess-
ment of change in SBP. Overall, our data are consistent with current
literature suggesting that there is a range of SBP that may be associ-
ated with differential outcomes for HFpEF patients presenting with
decompensated HF and the optimal target SBP needs to be better
studied and defined.
With regard to heart rate changes during hospitalization,
increases in heart rate to initially maintain cardiac output also limit LV
filling time, which can reduce output over time and lead to worse
outcomes. β-Blocker therapy has been recommended in the latter sce-
nario for controlling heart rate in HF patients.19 Because β-blockers
also affect blood pressure, the broad utility of β-blockers in HFpEF
has not been clearly established.31 And, with conflicting evidence with
regard to ivabradine in patients with HFpEF, it is unclear if heart-rate
reduction or other processes such as remodeling and improvement in
LVEF are the mechanism for potential benefits with this therapy.32–34
Further complicating the issue of heart rate in HFpEF is chronotropic
incompetence, or an abnormal response in heart rate during peak
dynamic exercise, which itself predicts mortality.35,36 In studies of
HFpEF patients, even in those not diagnosed with chronotropic
incompetence by clinical criteria, heart rate does not augment appro-
priately with exercise or recover postexercise as compared with con-
trols, suggesting potential autonomic dysregulation.37
In another post-hoc analysis of the TOPCAT trial, temporal
changes in heart rate during the trial were found to be independent
predictors of the composite endpoint of cardiovascular death, aborted
cardiac arrest, or HF hospitalization, with increase in heart rate over
time associated with higher risk.38 Although this study was in the out-
patient setting of chronic HFpEF patients, an analysis of patients with
HFpEF from the Organized Program to Initiate Lifesaving Treatment
in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry of
acute HF used propensity scores to match patients with discharge
heart rate < or ≥ 70 bpm.39 Lower heart rate was associated with
lower all-cause mortality in addition to the composite outcome of HF
rehospitalization and all-cause mortality during a median follow-up of
2.8 years.39 Although these studies have some notable differences as
previously described, they overall support our data that an elevated
heart rate is not favorable and suggests that there may be an element
of chronotropic pathology that warrants further study.
In contrast to HFpEF, in patients with HFrEF, both baseline SBP
and heart rate were associated with clinical outcomes at 180 days,
and heart rate increases from baseline to discharge were associated
with worse outcomes at 30 and 180 days. Thus, our data suggest that
rising heart rate during hospitalization, regardless of LVEF, portends
worse outcomes. In addition, higher SBP in HFrEF, similar to that of
FIGURE 1 Kaplan–Meier event curve for 180-day all-cause mortality in HFpEF patients by baseline SBP, with number at risk at 30-day intervals
from randomization by SBP. Abbreviations: HFpEF, heart failure with preserved ejection fraction; SBP, systolic blood pressure
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patients with HFpEF, is associated with improved outcomes, as sup-
ported by prior studies.20,40 These data provide a rationale for future
studies to assess whether interventions to maintain or reduce heart
rate during hospitalization improve outcomes.
With heart rate and SBP so intricately linked to one another, we
assessed the product of both in the RPP to determine if this would be
a useful measurement with regard to prognostic assessment. Baseline
RPP was not associated with outcomes in either HFpEF or HFrEF
patients. However, the change in RPP—an increase in RPP from base-
line to discharge—was associated with increased 30-day mortality and
HF rehospitalization in both HFpEF and HFrEF. Interestingly, this
seems to be driven differently in each population; with HFpEF, RPP
was driven by both heart rate and SBP, whereas in HFrEF, the prog-
nostic utility of RPP was driven largely by heart rate, suggesting possi-
ble different pathophysiological mechanisms or adaptive physiology
of HFpEF compared with HFrEF. Of note, we did not find any addi-
tional associative information with the baseline RPP variable as com-
pared with baseline SBP and heart rate variables alone for both
primary and secondary outcomes.
4.1 | Study limitations
This was a retrospective analysis and causal relationships cannot be
determined. There were strict inclusion/exclusion criteria that may
not apply to all HF patients. HFpEF was defined with an LVEF cutoff
of 40%, and this definition varies in other studies. Information regard-
ing heart rate and SBP was taken from documented single values that
may not be representative of the longitudinal hemodynamic state of
the patient and may be better captured by more data points. Further-
more, baseline vital signs were measured at time of enrollment, which
may not have been consistent with heart rate and SBP at time of ini-
tial presentation with acute decompensated HF. In these circum-
stances, heart rate and SBP may not truly be representative of true
“baseline” values, as these patients may have already been treated
with medications or have had shifts in their hemodynamics by the
time of enrollment. Our study focused on acute decompensated HF
patients and may not be applicable to chronic HF patients. We did not
find a significant difference between HFpEF and HFrEF based on
interaction analyses; however the HFrEF population was significantly
larger than the HFpEF population, and the analysis may have been
underpowered.
5 | CONCLUSION
Our data describe the associations of clinical outcomes with heart rate
and SBP in acute HF exacerbation, with a focus on patients with
HFpEF. In general, patients with lower heart rate had more comorbid-
ities and higher usage of therapies to control heart rate compared
with patients with higher heart rate. Baseline SBP was associated with
180-day all-cause mortality in an inverse manner. Further, change in
heart rate and SBP from baseline to discharge was associated with
30-day all-cause mortality or HF rehospitalization. These findings
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during hospitalization and suggest potential opportunities to target
these parameters with therapies to improve outcomes.
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